When the FDA convened the first hearing about CBD a week ago Friday, The New York Times described the event as “one hot ticket.” Apparently over 400 experts originally requested to speak, yet the list was narrowed down to 120 people who were given 2-4 minutes to state their case. There will be ample time to submit … Continue reading Why All the Fuss?